ADRA1 modulators(Adrenergic receptor alpha-1 modulators), ADRA2 modulators(Adrenergic receptors alpha-2 modulators), AMPA receptor modulators(Glutamate receptor ionotropic AMPA modulators)

+ [5]

Therapeutic Areas

Other Diseases

Active Indication

Depressive Disorder

Inactive Indication-

Originator Organization

Peking University Health Science Center

Active Organization

Peking University Health Science Center

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with YH-200

100 Translational Medicine associated with YH-200

100 Patents (Medical) associated with YH-200

Literatures (Medical) associated with YH-200

01 Aug 2015·Acta Pharmacologica SinicaQ1 · MEDICINE

Involvement of adrenoceptors, dopamine receptors and AMPA receptors in antidepressant-like action of 7-O-ethylfangchinoline in mice

Q1 · MEDICINE

Article

Author: Ding, Hui ; Xu, Ya-ping ; Sheng, Zhao-fu ; Zhang, Yong-he ; Cui, Su-ying ; Zhang, Xue-qiong ; Yang, Guang ; Yu, Bin ; Lin, Zhi-ge ; Cui, Xiang-yu ; Huang, Yuan-li ; Cao, Qing ; Song, Jin-zhi ; Li, Sheng-jie

AIM7-O-ethylfangchinoline (YH-200) is a bisbenzylisoquinoline derivative. The aim of this study was to investigate the antidepressant-like action and underlying mechanisms of YH-200 in mice.METHODSMice were treated with YH-200 (15, 30, and 60 mg/kg, ig) or tetrandrine (30 and 60 mg/kg, ig) before conducting forced swimming test (FST), tail suspension test (TST), or open field test (OFT).RESULTSYH-200 (60 mg/kg) significantly decreased the immobility time in both FST and TST, and prolonged the latency to immobility in FST. YH-200 (60 mg/kg) was more potent than the natural bisbenzylisoquinoline alkaloid tetrandrine (60 mg/kg) in FST. Pretreatment with α1-adrenoceptor antagonist prazosin (1 mg/kg), β-adrenoceptor antagonist propranolol (2 mg/kg), dopamine D1/D5 receptor antagonist SCH23390 (0.05 mg/kg), dopamine D2/D3 receptor antagonist haloperidol (0.2 mg/kg) or AMPA receptor antagonist NBQX (10 mg/kg) prevented the antidepressant-like action of YH-200 (60 mg/kg) in FST. In contrast, pretreatment with α2 adrenoceptor antagonist yohimbine (1 mg/kg) augmented the antidepressant-like action of YH-200 (30 mg/kg) in FST. Chronic administration of YH-200 (30 and 60 mg/kg for 14 d) did not produce drug tolerance; instead its antidepressant-like action was strengthened. Chronic administration of YH-200 did not affect the body weight of mice compared to control mice.CONCLUSIONYH-200 exerts its antidepressant-like action in mice via acting at multi-targets, including α1, α2 and β-adrenoceptors, D1/D5 and D2 /D3 receptors, as well as AMPA receptors.

01 Nov 1995·Clinical and Experimental Pharmacology and Physiology

ROLE OF NITRIC OXIDE IN THE CONTROL OF BLOOD PRESSURE IN YOUNG AND ADULT SPONTANEOUSLY HYPERTENSIVE RATS

Article

Author: K. Kawashima ; K. Fujimoto ; H. Amano ; T. Suzuki ; T. Fujii ; N. Yamaguchi ; Y. Akiba

Summary1. The depressor response to sodium nitroprusside (SNP) and the pressor response to Nω‐nitro‐L‐arginine methyl ester (L‐NAME) were investigated in anaesthetized and ganglion‐blocked 6 week old (young) and 20 week old (adult) spontaneously hypertensive rats (SHR), and the results were compared with those in age‐matched normotensive Wistar‐Kyoto (WKY) rats.2. SNP produced a dose‐dependent decrease of the mean blood pressure (BP) in both strains, and no differences in vascular sensitivity to SNP were observed between the strains.3. L‐NAME caused dose‐dependent pressor responses in both strains. The sensitivity and the maximal response to L‐NAME in SHR were significantly greater than those in age‐matched WKY (P < 0.05 or 0.01; t‐test, 13d.f. in both ages). However, there were no significant differences in the responses between ages in each strain.4. Acute reduction of BP induced by 7‐O‐ethylfangchinoline did not affect the responses to SNP and L‐NAME in the adult SHR.5. These results indicate that a greater amount of NO is tonically released in SHR and that its contribution to BP control is greater in SHR than in WKY, whereas vascular sensitivity to NO does not differ between the strains. In addition, acute changes in BP do not affect the degree of dependency on NO for BP control.

01 Nov 1995·Clinical and Experimental Pharmacology and Physiology

ANTIHYPERTENSIVE EFFECTS, DETERMINED BY A TELEMETRY METHOD, OF TRICHLOROMETHIAZIDE AND 7–O‐ETHYLFANGCHINOLINE, A DERIVATIVE OF TETRANDRINE, IN SPONTANEOUSLY HYPERTENSIVE RATS

Article

Author: K. Kawashima ; T. Suzuki ; T. Negishi ; H. Amano ; T. Fujii ; K. Fujimoto

Summary1. The antihypertensive effects of 10 mg/kg trichloromethiazide (TCM), 10 mg/kg 7–O‐ethylfangchinoline (7–O‐EFC) and the combination of these drugs given orally once daily for 2 weeks were investigated by measuring the blood pressure (BP), heart rate (HR) and activity in conscious, freely moving spontaneously hypertensive rats (SHR) fitted with a telemetry device.2. Clear diurnal rhythms of the HR and activity in synchrony with the light/dark cycle were observed during therapy, whereas the BP rhythm was obscure.3. Alone, TCM and 7–O‐EFC produced slight and insignificant reductions of 24 h mean BP, whereas in combination they produced an additive and significant BP reduction, compared with the vehicle‐treated controls, from the third day of therapy. The BP reduction induced by the combination of these drugs during the dark phase was more marked than that during the light phase.4. None of the drug therapies affected the HR and activity diurnal rhythms.5. The results of the present study demonstrate that the telemetry method is useful for monitoring the antihypertensive effects of drugs in SHR under physiological conditions with minimal stress.

100 Deals associated with YH-200

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder	Preclinical	CN	Peking University Health Science Center	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

YH-200

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation